NCT06512584 Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
| NCT ID | NCT06512584 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
| Condition | Short Bowel Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2024-09-03 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 72 participants in total. It began in 2024-09-03 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are: * How effective is PJ009 in treating short bowel syndrome? * Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS. Participants will * Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks, * Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment, * Keep a diary of the amount of their parenteral nutrition/ intravenous fluids (PN/IV), enteral nutrition and urine volume.
Eligibility Criteria
Inclusion Criteria: 1. Male and female aged ≥ 14 years; 2. SBS patients dependent on PN/IV support for at least 6 consecutive months due to major intestinal resection; 3. At least 3 PN/IV support sessions per week are required 1 week before screening or 2 weeks before baseline; 4. Be on stable PN/IV support for at least 4 consecutive weeks before administration; 5. For subjects with a history of Crohn's disease (CD), clinical assessment of remission for at least 12 weeks prior to administration; 6. Be able to understand and provide signed informed consent, for those under 18 years old, the guardian should also sign the informed consent; 7. Be able to complete experiments in accordance with the protocol. Exclusion Criteria: 1. Have used teduglutide in the past or may be allergic to teduglutide or its components; 2. Have used natural GLP-2 or its analogs, human growth hormone or its analogs within 6 months before screening; 3. Have used glutamine, octreotide, GLP-1 analogs or dipeptidyl peptidase-IV inhibitors within 30 days before screening; 4. With active Crohn's disease or those who need to change biological therapy within 6 months before screening; 5. With active inflammatory bowel disease (IBD) or IBD patients who have received immunosuppressant therapy changes in the past 3 months; 6. With unstable absorption due to cystic fibrosis, untreated megacolon disease or known DNA abnormalities (such as familial adenomatous polyposis, Fanconi syndrome); 7. With clinically obvious intestinal obstruction or active stenosis within 6 months before screening; 8. Have undergone major gastrointestinal surgical intervention within 3 months before screening, such as continuous transverse enteroplasty or other intestinal lengthening surgery (esophageal intubation or endoscopic surgery is allowed); 9. Severe active, uncontrolled, untreated systemic diseases (such as cardiovascular, respiratory, renal, infectious, endocrine, liver or central nervous system diseases, etc.); 10. Have malignant tumors within 5 years before screening (except for fully treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery); 11. With severe liver function impairment: 1. Total bilirubin ≥ 2.0 × upper limit of normal (ULN); for patients with Gilbert's syndrome, direct bilirubin ≥ 2.0 × ULN; 2. Aspartate transaminase (AST) ≥ 5.0 × ULN, alanine transaminase (ALT) ≥5.0 × ULN; 12. With renal function impairment: 1. Serum creatinine ≥2.0 × ULN; 2. Creatinine clearance \< 60 ml/min (calculated according to the Cockcroft-Gault formula, see Appendix 3 for details); 13. Pancreatic abnormalities: 1. Serum amylase ≥ 2.0 × ULN; 2. Serum lipase ≥ 2.0 × ULN; 14. More than 4 SBS or PN-related hospitalizations (such as catheter sepsis, intestinal obstruction, severe water and electrolyte disorders) within 12 months before screening; 15. Unplanned hospitalization within 30 days before screening; 16. Pregnant or lactating women, women or men who have fertility plans or do not agree to take effective contraceptive measures during the trial; 17. Participated in any clinical trial (excluding antibody treatment-related clinical trials) within 30 days before screening or participated in any antibody treatment-related clinical trials within 3 months before screening; 18. Other condition the investigator believes would be unsuitable for participation in this clinical study.
Contact & Investigator
Huanlong Qin
PRINCIPAL INVESTIGATOR
Shanghai 10th People's Hospital
Frequently Asked Questions
Who can join the NCT06512584 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Short Bowel Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06512584 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 72 participants.
Is NCT06512584 currently recruiting?
Yes, NCT06512584 is actively recruiting participants. Contact the research team at sunj@pegbiocq.com for enrollment information.
Where is the NCT06512584 trial being conducted?
This trial is being conducted at Beijing, China, Chongqing, China, Guangzhou, China, Changsha, China and 4 additional locations.
Who is sponsoring the NCT06512584 clinical trial?
NCT06512584 is sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. The principal investigator is Huanlong Qin at Shanghai 10th People's Hospital. The trial plans to enroll 72 participants.